

Voyager Therapeutics Appoints Perry A. Karsen to Board of Directors

July 1, 2015 3:12 PM ET

Cambridge, Mass., July 1, 2015 – [Voyager Therapeutics, Inc.](#), a clinical-stage genetherapy company developing life-changing treatments for severe diseases of the centralnervous system (CNS), today announced the appointment of Perry A. Karsen to its boardof directors. Mr. Karsen brings more than 30 years of experience in thebiopharmaceutical industry and currently serves as chief executive officer of CelgeneCellular Therapeutics (CCT), the cell therapy research and development division ofCelgene Corporation.

“I am delighted to welcome Perry to Voyager’s board of directors,” said Steven Paul,M.D., president and CEO of Voyager Therapeutics. “Perry’s extensive managementexperience and proven track record of leadership in the biopharmaceutical industry willbe invaluable as Voyager evolves and advances its pipeline of gene therapies for patientswith severe CNS diseases.”

Mr. Karsen has been the CEO of CCT since May 2013, previously serving as CelgeneCorporation’s executive vice president and chief operations officer. Previously, Mr.Karsen was the president and CEO of Pearl Therapeutics, Inc., a privately heldbiotechnology company subsequently acquired by AstraZeneca plc. He joined Pearl fromCelgene, where he was senior vice president and head of worldwide businessdevelopment, responsible for emerging businesses as president, Asia/Pacific Region, aswell as all licensing and strategic collaboration initiatives. Prior to his tenure withCelgene, Mr. Karsen held multiple leadership positions including vice president, businessdevelopment at Human Genome Sciences, Inc.; vice president, strategic business analysisand development at Bristol-Myers Squibb Co.; senior vice president, marketing and salesat Zimmer, Inc.; director, business development and representative director, Japan atGenentech, Inc.; and various domestic and international roles with Abbott Laboratories.Additionally, he was a general partner at Pequot Ventures responsible for early and latestage investments in biotechnology and medical devices. Mr. Karsen currently serves as amember of the board of directors of the Biotechnology Industry Organization (where healso serves on the executive committee), the Life Sciences Foundation, Inc., AgiosPharmaceuticals, Inc. and Alliqua BioMedical, Inc. Mr. Karsen received a Masters ofManagement from Northwestern University, Kellogg School of Management, a Mastersin Teaching of Biology from Duke University and a B.S. in Biological Sciences from theUniversity of Illinois, Urbana-Champaign.

“Voyager Therapeutics is advancing its promising gene therapies against some of themost pressing medical needs facing society,” said Perry Karsen. “I am very excited to bejoining the Voyager board of directors, as Steve and the Voyager team continue toadvance these potentially transformational therapies to patients afflicted with severe CNSdiseases.”

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changingtreatments for severe diseases of the central nervous system. Voyager is committed toadvancing the field of AAV (adeno-associated virus) gene therapy through innovationand investment in vector engineering and optimization, manufacturing and dosing anddelivery techniques. The company’s pipeline is focused on severe CNS diseases in needof effective new therapies, including advanced Parkinson’s disease, a monogenic form ofamyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, and Huntington’s disease.Voyager has broad strategic collaborations with Genzyme Corporation, a Sanoficompany, and the University of Massachusetts Medical School. Founded by scientificand clinical leaders in the fields of AAV gene therapy, expressed RNA interference andneuroscience, Voyager Therapeutics was launched in 2014 with funding from leading lifesciences investor Third Rock Ventures, and is headquartered in Cambridge,Massachusetts. For more information, please visit www.voyagertherapeutics.com. FollowVoyager on [LinkedIn](#).

###

Voyager Therapeutics Media Contact:

Katie Engleman

Pure Communications, Inc.

910-509-3977

Katie@purecommunicationsinc.com